Andrew McClean

Andrew McLean

Is currently Life Sciences Head at Oxford Science and Innovation. Andy joined OSI from McKinsey & Co. At McKinsey he was deeply embedded in both the private equity and pharmaceuticals practices. He is a physician with training in orthopaedic surgery who also completed a degree in philosophy, politics and economics at Christ Church, Oxford. He cut his investing teeth on the trading floor at Goldman Sachs.

Nicholas La Thangue 2

Nicholas La Thangue

Nick is a founder of Argonaut Therapeutics and Professor of Cancer Biology at the University of Oxford. He is a Fellow of the Royal Society of Edinburgh, a Member of the European Molecular Biology Organisation (EMBO), a Fellow of the Academy of Medical Sciences, a Fellow of the Lister Institute and Professorial Fellow at Linacre College Oxford. Nick has founded several companies, including Prolifix, Celleron Therapeutics and Oxford Cancer Biomarkers, and has extensive experience derived from the biotechnology and pharmaceutical sectors.